Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics develops molecular glue degrader medicines for serious diseases using its QuEEN discovery engine, which combines AI-guided chemistry, chemical libraries, structural biology and proteomics. The company’s news centers on clinical and preclinical updates for programs including MRT-8102, a NEK7-directed degrader for inflammatory disease biology; MRT-2359, a GSPT1-directed degrader studied in metastatic castration-resistant prostate cancer; and MRT-6160, a VAV1-directed degrader for immune-mediated diseases.
Recurring developments also include oncology discovery work such as cyclin E1-directed and CDK2-directed degrader programs, clinical supply and pharmaceutical collaboration activity, quarterly financial results, equity awards, capital resources and public-company governance updates.
Monte Rosa Therapeutics (NASDAQ: GLUE) announced positive interim Phase 1 data for MRT-8102, a NEK7-directed oral molecular glue degrader targeting NLRP3/IL-1/IL-6 inflammation pathways. In Part 3 (24 subjects dosed for 4 weeks as of Dec 23, 2025) median hsCRP fell 85% and 94% of subjects reached hsCRP <2 mg/L from a median baseline of 6.3 mg/L. NEK7 degradation in peripheral T cells was ~80–90% across doses (5–400 mg). Median plasma IL-6 dropped 55%; two subjects had a 75% CSF IL-6 decrease. Safety was described as favorable with mainly mild–moderate AEs and no evidence of increased infection risk. Readout of the expanded study is anticipated in H2 2026, and a Phase 2 ASCVD study is planned for 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present interim clinical results for the NEK7-directed molecular glue degrader MRT-8102 on Jan 7, 2026 at 8:00 a.m. ET. The presentation will highlight interim data from the ongoing Phase 1 study, including the Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.
The event will be available via live conference call and webcast through the company’s Events & Presentations page at ir.monterosatx.com, with an archived webcast accessible for 30 days after the presentation.
Monte Rosa Therapeutics (Nasdaq: GLUE)/b) reported interim Phase 1/2 data for in heavily pretreated mCRPC patients as of Dec 3, 2025. Of 20 enrolled (14 RECIST-evaluable), the AR-mutant subgroup (4 patients) showed a 100% PSA response rate (4/4), including two PSA90s, and a 100% disease control rate with two RECIST responses. Overall RECIST-evaluable DCR was 64% (9/14). Safety was manageable, primarily Grade 1–2 gastrointestinal events. The company plans a signal-confirming Phase 2 (up to 25 patients) beginning in 2026 and will present updated data at ASCO GU in Feb 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present updated interim results from the Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.
The company will host a live conference call and webcast on December 16, 2025 at 8:00 a.m. ET. The presentation will be available via Monte Rosa’s investor site under “Events & Presentations,” and an archived webcast will be accessible for 30 days after the event.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present preclinical data on MRT-8102, a first-in-class NEK7-directed molecular glue degrader, at AHA Scientific Sessions 2025 on Nov 8, 2025 at 10:30 a.m. CST.
Key findings showed selective, potent, and durable NEK7 degradation with in vitro and in vivo inhibition of the NLRP3 inflammasome, suppression of multiple cytokines, inhibition of pyroptosis in human macrophages, and near-complete IL-1β and Caspase-1 suppression in ex vivo whole blood from orally dosed cynomolgus monkeys. The company is enrolling a Phase 1 study and expects initial healthy-volunteer and elevated CVD-risk data in H1 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q3 2025 results and business updates highlighting a new collaboration with Novartis and multiple clinical programs advancing.
Key facts: $120.0M non-refundable upfront from Novartis, up to $5.7B total deal value, Q3 collaboration revenue $12.8M, cash and marketable securities $396.2M as of Sept 30, 2025, and a stated cash runway to fund operations through 2028. Clinical highlights include MRT-8102 Phase 1 initial readout on track for H1 2026, MRT-6160 advancing toward Phase 2 with Novartis, and MRT-2359 updated data expected by year-end 2025. Company plans IND submissions in 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced that CEO Markus Warmuth, M.D. will participate in fireside chats at four investor conferences in November–December 2025.
Scheduled participations: Guggenheim Healthcare Innovation (Boston) on Nov 10, 2025 at 11:30 a.m. ET; TD Cowen Immunology & Inflammation Summit (virtual) on Nov 13, 2025 at 12:00 p.m. ET; Jefferies Global Healthcare (London) on Nov 18, 2025 at 11:30 a.m. GMT; and Piper Sandler Healthcare (New York) on Dec 2, 2025 at 1:30 p.m. ET.
Webcasts will be available via the company’s Events & Presentations page at ir.monterosatx.com and archived for 30 days after each presentation.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced preclinical data for MRT-6160, a VAV1-directed molecular glue degrader, showing broad activity in immune cells and disease reduction in a spontaneous autoimmune MRL-Faslpr mouse model.
Key reported effects include attenuated autoantibody production, reduced proteinuria, lymphadenopathy, skin lesions, organomegaly, and kidney glomerular and interstitial nephritis. The company reported MRT-6160 was equivalent or superior to prednisone and an anti-CD40L antibody across multiple pathology metrics. In vitro, MRT-6160 decreased TfH-mediated B cell activation and immunoglobulin secretion. Monte Rosa said it continues to work with Novartis to advance MRT-6160 toward Phase 2 studies. Poster presentation: October 26, 2025, 10:30–12:30 pm CDT (Poster #0009).
Monte Rosa Therapeutics (Nasdaq: GLUE) has announced a significant collaboration with Novartis to develop novel molecular glue degrader (MGD)-based medicines for immune-mediated diseases. The deal includes an upfront payment of $120 million to Monte Rosa, with potential total deal value reaching $5.7 billion plus tiered royalties.
This marks Monte Rosa's second collaboration with Novartis, following their October 2024 agreement for VAV1 degraders. Under the new agreement, Monte Rosa will utilize its proprietary AI/ML-enabled QuEEN™ platform for degrader discovery and development, while Novartis receives an exclusive license to an undisclosed target and options to license two programs from Monte Rosa's preclinical immunology portfolio.
The collaboration strengthens Monte Rosa's financial position, enabling advancement of their wholly owned programs in autoimmune conditions and extending runway beyond multiple Phase 2 readouts for MRT-8102, MRT-6160, and MRT-2359.
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on molecular glue degrader (MGD)-based medicines, has announced its participation in two upcoming investor conferences. The company will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, in New York. Additionally, CEO Markus Warmuth will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 9:00 a.m. ET. The fireside chat will be available via webcast on the company's investor relations website.